Baidu
map

The Lancet Oncology:前列腺癌患者术后生活质量调查

2017-04-01 MedSci MedSci原创

如何选择早期前列腺癌的治疗方案极大影响患者的预后生活质量

对相应人群的前瞻性研究表明,根治性前列腺切除术、放疗等疗法的治疗副作用对于新诊断的局限性前列腺癌患者的预后生活质量有很大影响。

研究人员在治疗后的第3、12、24个月,通过电话对患者进行随访,对术后症状进行评分(0-100,分数越高,功能丧失症状越严重)。1141名患者中,有469名(41%)接受前列腺切除术、109人(10%)接受浅部放射治疗、249人(22%)接受体外放射治疗、314名(28%)接受主动的病情监测(保守治疗)。

在治疗3个月后,性功能障碍最严重的群组为前列腺切除术组,分数为36.2分、体外放射治疗组为13.9分、浅部放射治疗组为17.1分;前列腺切除术组尿失禁最严重为33.6分;尿路梗阻疼痛现象最严重的为浅部放射治疗组,20.5分;肠道症状最严重的为体外放射治疗组,4.9分。在第24个月主要不良症状的得分没有显着改变。

研究表明,相比于其他的治疗手段,根治性前列腺切除术更容易导致尿漏与性功能障碍;采用放射治疗的病人2年后的生活质量与保守治疗相近,这项研究将帮助医生和患者做出一个既不影响治疗也不降低患者预后生活质量的决定。

原文出处:

Priya Venkatesan et al. Quality of life after treatments for prostate cancer. The Lancet Oncology. 2017 Mar 30.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674396, encodeId=754d16e439666, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jan 21 06:52:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864872, encodeId=7e9518648e2e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Oct 17 15:52:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828847, encodeId=ed0a182884e5c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 04 12:52:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184409, encodeId=bf171844093c, content=要好好学习研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Sun Apr 02 02:55:47 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674396, encodeId=754d16e439666, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jan 21 06:52:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864872, encodeId=7e9518648e2e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Oct 17 15:52:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828847, encodeId=ed0a182884e5c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 04 12:52:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184409, encodeId=bf171844093c, content=要好好学习研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Sun Apr 02 02:55:47 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-10-17 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674396, encodeId=754d16e439666, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jan 21 06:52:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864872, encodeId=7e9518648e2e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Oct 17 15:52:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828847, encodeId=ed0a182884e5c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 04 12:52:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184409, encodeId=bf171844093c, content=要好好学习研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Sun Apr 02 02:55:47 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-08-04 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674396, encodeId=754d16e439666, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jan 21 06:52:00 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864872, encodeId=7e9518648e2e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Oct 17 15:52:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828847, encodeId=ed0a182884e5c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Aug 04 12:52:00 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184409, encodeId=bf171844093c, content=要好好学习研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40011656268, createdName=121485632188547785, createdTime=Sun Apr 02 02:55:47 CST 2017, time=2017-04-02, status=1, ipAttribution=)]
    2017-04-02 121485632188547785

    要好好学习研究下

    0

相关资讯

Nat Med:单独使用anti-CTLA4治疗前列腺癌效果差的原因

此项临床研究,阐明了anti-CTLA4疗法在对于治疗前列腺癌症疗效差的原因。发现了PD-L1以及VISTA的表达量在anti-CTLA4疗法后的表达量的上升。暗示了采用多种针对check point信号的疗法(anti-PD-L1, anti-VISTA)共同治疗前列腺癌症疗的效果可能更好。为下一步开发新的疗法提供了数据。

Cancer Cell:ERG基因拟肽类抑制剂用于治疗前列腺癌

转录因子在多种癌症的发展中发挥关键作用,而对治疗靶向的治疗仍然是一个挑战。在前列腺癌中,编码转录因子ERG的基因被重新排列并在前列腺癌发生中发挥关键作用。在这项研究中,研究人员利用大分子多肽来靶向ERG,他们在细胞系和动物模型中证明这种方法可以有效靶向并促进ERG融合蛋白的降解,对细胞正常功能几乎不会产生影响。

JAMA:局限性前列腺癌患者应如何选择适合自己的手术方式?

局限性前列腺癌的患者需要在不良反应各异的治疗策略中作出决定。近期,一项发表在权威杂志JAMA上的研究旨在比较根治性前列腺切除术、外放射治疗、近距离放射治疗与主动检测的生活质量(QOL)。此项研究为前瞻性队列研究,纳入了自2011年1月至2013年6月北卡罗来纳州中央癌症登记处的1141名(合格男性参与57%)新诊断的前列腺癌人群。从诊断到入院的中位时间为5周,所有男性在接受治疗前均已获得书面知情同

Oncogene:脑发育蛋白/EB3通路促进前列腺癌侵入活性

前列腺癌是男性群体中常见的癌症,并且目前的转移性前列腺癌无法治愈。最近,研究人员在研究中展示了drebrin/EB3通路协调了动态微管/肌动蛋白丝与响应导向因子的潜在细胞性状变化的交流 ,且该通路在前列腺癌细胞侵入中有重要作用。研究发现,在良性人类前列腺中,脑发育蛋白(drebrin)限制在基部上皮细胞中表达;而在恶性前列腺癌症病灶中,该蛋白在内腔上皮细胞中表达上调。研究还发现,脑发育蛋白在人类前

CANCER RES;靶向TBX2-WNT信号的路治疗前列腺癌骨转移

对于晚期前列腺癌患者,找到肿瘤细胞骨转移以及后续骨重塑的影响因素对于肿瘤治疗有重要的意义。TBX2是T-box家族的转录因子,可以负向调节细胞周期抑制剂p21,在胚胎发育过程中扮演关键角色。研究表明其在肿瘤病程中同样起到重要作用。

Sci Rep:受ELF5调节的AR激活可以调控前列腺癌的进展

转录因子的类E74因子5(ELF5)是一个有效的抗癌基因,它可以防止上皮-间质转化(EMT)和前列腺癌(PCa)的转移。然而,对于它如何抑制肿瘤的生长和是否它能够与雄激素受体(AR)互作却知道的很少。最近,研究人员发现,ELF5在AR激活的PCa细胞中频繁表达。并且,在PCa细胞中,ELF5可以和AR结合,扮演一个生理的伙伴角色,并且ELF5可负调控AR的转录活性。另外,研究还发现,ELF5与AR

Baidu
map
Baidu
map
Baidu
map